P1.14-05 TROP2 Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells

Abstract

Malignant pleural mesothelioma (MPM) is a rare disease with a grim prognosis. Despite the fact that immune checkpoint inhibitors were recently approved as a potential first line therapy beside platinum based chemotherapy a large portion of patients are not responding or acquire resistance following treatment. Irinotecan (CPT-11) is a topoisomerase I inhibitor that is an approved drug in several cancer types. Its active metabolite, SN38 has a 100-1000 fold stronger cytotoxicity. It can be efficiently delivered in antibody - drug conjugates as sacituzumab govitecan where it is attached to the trophoblast cell-surface antigen 2 (TROP-2).